These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 1127967)

  • 1. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage.
    Bull BS; Huse WM; Brauer FS; Korpman RA
    J Thorac Cardiovasc Surg; 1975 May; 69(5):685-9. PubMed ID: 1127967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols.
    Bull BS; Korpman RA; Huse WM; Briggs BD
    J Thorac Cardiovasc Surg; 1975 May; 69(5):674-84. PubMed ID: 1127966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin administration during extracorporeal circulation: heparin rebound and postoperative bleeding.
    Kaul TK; Crow MJ; Rajah SM; Deverall PB; Watson DA
    J Thorac Cardiovasc Surg; 1979 Jul; 78(1):95-102. PubMed ID: 449391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of heparin therapy.
    Gervin AS
    Surg Gynecol Obstet; 1975 May; 140(5):789-96. PubMed ID: 1170648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Control of temporary anticoagulation in extracorporeal circulation using activated coagulation time].
    Kessler G; Grünes G
    Anaesthesist; 1984 Dec; 33(12):588-91. PubMed ID: 6528961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery.
    Babka R; Colby C; El-Etr A; Pifarré R
    J Thorac Cardiovasc Surg; 1977 May; 73(5):780-2. PubMed ID: 850438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass.
    Akl BF; Vargas GM; Neal J; Robillard J; Kelly P
    J Thorac Cardiovasc Surg; 1980 Jan; 79(1):97-102. PubMed ID: 7350393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety issues in heparin and protamine administration for extracorporeal circulation.
    Jobes DR
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of blood coagulation in open heart surgery. II. Use of individualized dosages of heparin and protamine controlled by activated coagulation times.
    Dercksen SJ; Linssen GH
    Acta Anaesthesiol Belg; 1980; 31(2):121-8. PubMed ID: 7468138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated clotting time for control of anticoagulation during surgery.
    Lefemine AA; Lewis M
    Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of the determination of activated coagulation time for decreasing heparin and protamine sulfate doses during operations with artificial circulation].
    Savina ME; Piatnitskaia GK; Kukaeva EA; Charnaia MA; Charnyĭ ISh
    Anesteziol Reanimatol; 1981; (5):52-6. PubMed ID: 7325386
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical evaluation of heparin concentration and activated clotting time monitoring (HEPCON HMS) system].
    Sakurada T; Kikuchi Y; Koushima R; Nakashima S; Hachiro Y; Kagaya H
    Nihon Kyobu Geka Gakkai Zasshi; 1997 Jun; 45(6):836-40. PubMed ID: 9217380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heparinization control by activated coagulation time in cardiac surgery with extracorporeal circulation].
    Daudt CA; Pereira SN; Moraes LB; Costa PS; Deboni LM; Figueiredo MS
    Arq Bras Cardiol; 1989 Mar; 52(3):137-9. PubMed ID: 2597000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation.
    Ottesen S; Stormorken H; Hatteland K
    Scand J Thorac Cardiovasc Surg; 1984; 18(2):123-8. PubMed ID: 6611586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of blood coagulation in open heart surgery. I. Effects of conventional dosages of heparin and protamine.
    Dercksen SJ; Linssen GH
    Acta Anaesthesiol Belg; 1980; 31(2):113-9. PubMed ID: 7468137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of a reduced dose of protamine after cardiopulmonary bypass.
    Guffin AV; Dunbar RW; Kaplan JA; Bland JW
    Anesth Analg; 1976; 55(1):110-3. PubMed ID: 1108703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of activated coagulation time to monitor heparin during cardiac surgery.
    Roth JA; Cukingnan RA; Scott CR
    Ann Thorac Surg; 1979 Jul; 28(1):69-72. PubMed ID: 454047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Haemochron--a simple method of monitoring heparin level during extracorporeal circulation].
    Saggau W; Lüllig H; Storch HH; Tanzeem A; Schmitz W; Hissen W
    Chir Forum Exp Klin Forsch; 1978; (1978):119-22. PubMed ID: 752575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical evaluation of the Hepcon/HMS: a new device of monitoring hemostasis management during cardiopulmonary bypass].
    Yamanishi H; Watanabe S; Hayashi K; Tomioka H; Minami M; Nozaki Y; Aoki T; Kawai Y; Kishino K; Ohta S
    Kyobu Geka; 1997 Jun; 50(6):459-62. PubMed ID: 9185440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.